In RAW264.7 cells, ABAI-30 (10-40 μM) inhibits the TLR4-pp65 and NLRP3-caspase-1 signaling pathway, thus leading to the downregulation of IL6, IL-1β and TNFα at both transcriptional and translational levels [1].

In a dextran sulfate sodium (DSS)-induced colitis mouse model, ABAI-30 (25 mg/kg; oral administration; for 5 days) demonstrates high in vivo anti-inflammatory efficacy without causing obvious toxicity [1].